← Back to headlines
AbbVie's Apogee Deal to Extend Immunology Dominance
AbbVie's $10.9 billion acquisition of Apogee is expected to strengthen its leadership in the immunology market, prompting analysis on whether it's a good time for investors to buy shares.
22 Jun, 22:56 — 22 Jun, 22:56
Sources
Showing 1 of 1 sources
Related Stories
Mykhailo Mudryk Joins Tottenham on Loan from Chelsea
20m ago
Netanyahu Accuses Security Officials of Deliberately Not Waking Him on October 7
23m ago
Two Injured After Explosion Near Augsburg Train Station in Germany
33m ago
Zelenskyy Warns Airlines to Avoid Russian Airspace; Putin Calls It State Terrorism
34m ago